Kerry Lynn Reynolds, M.D.
Co-Author
This page shows the publications co-authored by Kerry Reynolds and Steven Chen.
Connection Strength
3.311
-
Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy. Br J Dermatol. 2022 Mar 15.
Score: 0.248
-
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors. Eur J Cancer. 2022 Mar 05; 166:21-23.
Score: 0.248
-
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. J Am Acad Dermatol. 2022 Feb 19.
Score: 0.247
-
Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid. Eur J Cancer. 2021 12; 159:34-37.
Score: 0.242
-
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
Score: 0.239
-
Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA Dermatol. 2021 05 01; 157(5):577-582.
Score: 0.234
-
Response to: "Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions". J Am Acad Dermatol. 2021 08; 85(2):e111-e112.
Score: 0.233
-
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
Score: 0.232
-
Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. Eur J Cancer. 2021 01; 142:143-146.
Score: 0.225
-
Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. J Am Acad Dermatol. 2020 Nov; 83(5):1475-1477.
Score: 0.216
-
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
Score: 0.211
-
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
Score: 0.211
-
Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. J Am Acad Dermatol. 2020 04; 82(4):994-996.
Score: 0.209
-
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746.
Score: 0.207
-
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. 2022 03; 86(3):563-572.
Score: 0.058
-
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999.
Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.